Compare CORT & ENLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CORT | ENLT |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.1B |
| IPO Year | 2001 | 2022 |
| Metric | CORT | ENLT |
|---|---|---|
| Price | $121.38 | $67.38 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 8 |
| Target Price | ★ $141.00 | $86.14 |
| AVG Volume (30 Days) | ★ 872.9K | 144.8K |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $761,407,000.00 | N/A |
| Revenue This Year | $50.53 | $61.76 |
| Revenue Next Year | $48.75 | $41.88 |
| P/E Ratio | $1,317.11 | ★ $76.10 |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $32.75 |
| 52 Week High | $126.38 | $108.65 |
| Indicator | CORT | ENLT |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 40.21 |
| Support Level | $108.33 | $64.64 |
| Resistance Level | $123.01 | $79.81 |
| Average True Range (ATR) | 5.11 | 1.46 |
| MACD | 0.39 | 0.09 |
| Stochastic Oscillator | 83.38 | 27.84 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, producing its revenue from the sale of the electricity which is produced through wind energy and solar energy in Europe.